Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023 4:01 PM EST

- THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 -

- Timing for the selection of lead subcutaneous TED program is on track for the end of 2023 -

- Advancing recently announced novel preclinical portfolio of potentially best-in-class neonatal Fc receptor (FcRn) inhibitors with the broad potential to treat autoimmune diseases -

- Announced the appointment of Stephen Mahoney as... More